Match!
Elizabeth Page
Institute of Cancer Research
40Publications
9H-index
1,122Citations
Publications 40
Newest
Abstract Background Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. Objective To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Design, setting, and participants Men aged 40–69 yr with a germline pathogenic BRC...
#1Elizabeth BancroftH-Index: 19
#2Sibel SayaH-Index: 4
Last.Neil K. Aaronson (NKI-AVL: Netherlands Cancer Institute)H-Index: 98
view all 27 authors...
Objectives To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. Particpants and Methods Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the f...
#1Christos Mikropoulos (U of C: University of Chicago)H-Index: 4
#2Christina G. Selkirk (U of C: University of Chicago)H-Index: 8
Last.Rosalind A. Eeles (U of C: University of Chicago)H-Index: 93
view all 120 authors...
BACKGROUND: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort. METHODS: PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in m...
#1Clare Moynihan (ICR: Institute of Cancer Research)H-Index: 23
#2Elizabeth Bancroft (ICR: Institute of Cancer Research)H-Index: 19
Last.Rosalind A. Eeles (ICR: Institute of Cancer Research)H-Index: 93
view all 7 authors...
ObjectiveIncreased risk of prostate cancer (PCa) is observed in men with BRCA1/BRCA2 mutations. Sex and gender are key determinants of health and disease although unequal care exists between the sexes. Stereotypical male attitudes are shown to lead to poor health outcomes. MethodsMen with BRCA1/2 mutations and diagnosed with PCa were identified and invited to participate in a qualitative interview study. Data were analysed using a framework approach. Masculinity theory was used to report the imp...
#1Emma KillickH-Index: 6
#2Richard MorganH-Index: 25
Last.Hardev PandhaH-Index: 46
view all 10 authors...
4653 Background: EN2 is part of the HOX gene family and plays a role in foetal development. More recently a potential oncogenic role for the protein has been postulated and its utility as a cancer biomarker has been explored in prostate cancer (PrCa) and breast cancer. Carriers of mutations in the BRCA1 and BRCA2 genes have an increased risk of PrCa (1.8-fold and 5-fold respectively) and their tumours tend to be more aggressive and advanced than sporadic cases. Currently there is no national scr...
#1Elena CastroH-Index: 15
#2David OlmosH-Index: 38
Last.Rosalind A. EelesH-Index: 93
view all 20 authors...
1545 Background: Biochemical relapse after local treatment for prostate cancer (PCa) indicates recurrent disease and is associated with shorter survival. Germline BRCA mutations are associated with worse PCa outcomes. BRCA carriers are currently treated with the same protocols used for non-carriers. We analyzed biochemical-progression free survival (bPFS) after conventional treatment for localized PCa in a cohort of BRCA patients (pts). Methods: In this retrospective case-control study, each BRC...
#1Elena CastroH-Index: 15
#2Elizabeth BancroftH-Index: 19
Last.Rosalind A. EelesH-Index: 93
view all 14 authors...
5054 Background: Prostate cancer (PC) screening is controversial and better approaches are needed, including a better assessment of individualized PC risk. Several studies have identified a number of common single nucleotide polymorphisms (SNPs) that confer a cumulative risk of PC. We have explored the potential role of genetic markers in identifying men who should be selectively targeted for screening in a population with increased risk of PC due to family history (FH) of the disease. Methods: ...
#1Elena Castro (National Health Service)H-Index: 15
#2Christos Mikropoulos (National Health Service)H-Index: 2
Last.Rosalind A. Eeles (National Health Service)H-Index: 93
view all 20 authors...
Background. A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not currently advocated. Approximately 100 common single nucleotide polymorphisms (SNPs) have been identified that are associated with the risk of developing PrCa. The PROFILE pilot study explored the feasibility of using SNP profiling in men with a family history (FH) of P...
#1Alexander DiasH-Index: 2
#2Sibel SayaH-Index: 4
Last.Rosalind A. EelesH-Index: 93
view all 11 authors...
INTRODUCTION AND OBJECTIVES: The relation of serum androgens and the development of prostate cancer (PCa) is subject of debate. Lower total testosterone (TT) levels have been associated with increased PCa detection and worse pathological features after treatment. The aim of this study is to investigate the association of serum androgens levels and PCa detection in a prospective screening study of men at higher genetic risk due to BRCA mutation METHODS: Six hundred and fifty seven participants in...
1234